-
Empire Analyst Sees 200% Upside To This Women's Health Biotech
Thursday, February 22, 2018 - 4:03pm | 295Read More...Viveve Medical Inc (NASDAQ: VIVE) is rapidly expanding — its sales force, its treatment indications, its revenue and its fan base, according to a bullish analyst. The Rating Empire Asset Management Company’s Dr. Cathy Reese initiated coverage on Viveve Medical with a Buy rating...
-
Empire Slaps $4 Target On Exact Sciences
Friday, February 26, 2016 - 9:40am | 251Read More...Empire Asset Management’s Dr. Cathy Reese maintained a Sell rating on EXACT Sciences Corporation (NASDAQ: EXAS), while revising the price target to $4. Exact Sciences reported 4Q15 revenues of $14.4 million and a net loss of about $40 million which was higher than the year ago net loss...
-
Sell Insulet, Empire Warns
Thursday, February 25, 2016 - 10:42am | 268Read More...Empire Asset Management issued a note on Insulet Corporation (NASDAQ: PODD) after recent analysis of the company's core business capabilities, specifically its insulin delivery pump "OmniPod." Analysts initiated coverage of Insulet with a Sell rating and a $15 price target....
-
Empire Analyst: Sell Sucampo Pharma, It Has 50% Downside
Tuesday, January 12, 2016 - 11:45am | 409Read More...Amid volatility, Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) shares have declined 21 percent over the past six months. Empire’s Dr. Cathy Reese initiating coverage of the company with a Sell rating and a price target of $7. The company has only one FDA approved drug, which could...
